Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma
Maiia Soloveva(Ministry of Health of the Russian Federation), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Igor Yakutik(Ministry of Health of the Russian Federation), Natalya Risinskaya(National Medical Research Center for Hematology), С. М. Куликов(Ministry of Health of the Russian Federation), А. М. Ковригина(Shupyk National Healthcare University of Ukraine), Andrey Sudarikov(National Medical Research Center for Hematology), Т. Н. Обухова(Ministry of Health of the Russian Federation), Bella Biderman(National Medical Research Center for Hematology), Yulia Chabaeva(National Medical Research Center for Hematology), M. V. Solovev(Ministry of Health of the Russian Federation), Elena Nikulina
Cited by 1
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
|Blood|2020|132
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59